[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Biotech Innovations
April 10, 2018

Patient-Derived Organoids Predict Cancer Treatment Response

JAMA. 2018;319(14):1427. doi:10.1001/jama.2018.3760

In a first-of-its-kind trial, researchers used tiny, simplified organs grown from patients’ cancer cells—so-called patient-derived organoids (PDOs)—to compare responses to anticancer agents in the laboratory and the clinic. The researchers focused on patients with chemotherapy-resistant metastatic gastrointestinal cancers. For these patients, targeted agents or novel investigational drugs can prolong survival, but in most cases no predictive biomarkers are available, so the process relies on trial and error.